Recent studies focusing on immune checkpoints, such as CTLA-4, LAG-3, PD-1, TIGHT, and TIM-3, have uncovered that these can significantly regulate the cancer immune function of TICs, leading to the inhibition of immune surveillance (Carosella et al., 2015; Manieri et al., 2017; Andrews et al., 2019). The gene discussed is HAVCR2; the disease is cancer.